Bristol-Myers preps second checkpoint/cancer vax combo study under its $1B Bavarian Nordic pact
Bristol-Myers Squibb is ready to launch its second combination trial using Bavarian Nordic’s cancer vaccine Prostvac.
Operating under a 2015 deal worth up to about a billion dollars, investigators will combine Prostvac with Yervoy and Opdivo in 10 patients with castration-resistant prostate cancer. Then they’ll push enrollment to 55 and divvy up the patients into three cohorts, studying T cell infiltration in tumors with one-on-one combos or the triple.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.